Synergistic immune and lipid metabolism targeting for metastatic prostate cancer therapy.

About Synergistic immune and lipid metabolism targeting for metastatic prostate cancer therapy.

Dr. Jennifer Wu and colleagues propose to evaluate a combinatorial strategy that recruits a prostate cancer patient’s immune system to eliminate castration resistant prostate cancer. The team has developed a novel antibody that suppresses growth of prostate tumors and prevents the progression to metastasis. This antibody, BSG510 targets the protein sMIC expressed by prostate tumors, and activates the immune system to specifically induce cell death in tumors.

Dr. Wu and her team have also developed a unique small molecule inhibitor, LCL521 that sensitizes tumors to attack by the immune system. Under the PCF- A. David Mazzone Challenge Award, Dr. Wu and her colleagues propose to therapeutically combine the immune stimulatory antibody and the small molecule inhibitor for 1) maximal activation of the immune system primed to kill cancer cells and 2) maximal sensitization of prostate tumors to immune cell killing. They will test the combination in ‘humanized’ prostate cancer mouse models that immunologically and pathologically recapitulate human disease. The researchers will evaluate whether the antibody+inhibitor combination can potentially synergize to eradicate primary and metastatic prostate cancer. They will also evaluate if this combination can potentially delay or prevent the progression of the disease to castration-resistance.

What this means for patients: Dr. Wu and her team are evaluating a combination of two therapies for the treatment of prostate cancer.

Principal Investigator:

Jennifer Wu, PhD (Medical University of South Carolina)

Co-investigators:

James Norris, PhD (MUSC), Michael Lilly, MD (MUSC), Xiang Liu, PhD (MUSC), Ali Goshayan, MD (MUSC)